SOMATULINE AUTOGEL 90 MG
LANREOTIDE (LANREOTIDE ACETATE) : 90 MG · DIN 02283409 · IPSEN BIOPHARMACEUTICALS CANADA INC
Health Canada status: MARKETED
What is SOMATULINE AUTOGEL?
SOMATULINE AUTOGEL 90 MG contains LANREOTIDE (LANREOTIDE ACETATE) : 90 MG. It is listed in the Health Canada Drug Product Database under DIN 02283409, held by IPSEN BIOPHARMACEUTICALS CANADA INC, supplied as SOLUTION (EXTENDED RELEASE) for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 16-Feb-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SOMATULINE AUTOGEL used for?
Long-term treatment of acromegaly; relief of acromegaly symptoms; treatment of Grade 1 or subset of Grade 2 enteropancreatic neuroendocrine tumours (NETs); treatment of carcinoid syndrome.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02283409 |
|---|---|
| Brand name | SOMATULINE AUTOGEL |
| Generic / active ingredient | LANREOTIDE (LANREOTIDE ACETATE) : 90 MG |
| Manufacturer | IPSEN BIOPHARMACEUTICALS CANADA INC |
| Strength | 90 MG |
| Dosage form | SOLUTION (EXTENDED RELEASE) |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | H01CB03 LANREOTIDE |
| AHFS class | 68:29.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Feb-2022 |
| Original market date | 2007-02-22 00:00:00 |
How is it administered?
90 mg every 4 weeks for 3 months, then adjust based on GH/IGF-1 levels. For NETs/Carcinoid: 120 mg every 4 weeks. Administered via deep subcutaneous injection.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 2°C to 8°C (Refrigerate). (Note: Section 11 details truncated but standard for this product).
How is it supplied?
Ready-to-use, sterile, pre-filled syringe (0.5 mL) with an automatic safety system. Available in 60 mg, 90 mg, and 120 mg doses.
Contraindications
Hypersensitivity to lanreotide, somatostatin, or related peptides; complicated, untreated lithiasis of the bile ducts.
Warnings and precautions
Loss of blood glucose control; gallbladder motility reduction/gallstone formation; sinus bradycardia; potential for allergic reactions (angioedema/anaphylaxis).
What can be used instead?
Other Canadian products sharing ATC code H01CB03 LANREOTIDE. 6 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MYTOLAC | 120 MG | SOLUTION (EXTENDED RELEASE) | ADVANZ PHARMA CANADA INC. | MARKETED | DIN 02555883 |
| MYTOLAC | 60 MG | SOLUTION (EXTENDED RELEASE) | ADVANZ PHARMA CANADA INC. | MARKETED | DIN 02555867 |
| MYTOLAC | 90 MG | SOLUTION (EXTENDED RELEASE) | ADVANZ PHARMA CANADA INC. | MARKETED | DIN 02555875 |
| SOMATULINE AUTOGEL | 120 MG | SOLUTION (EXTENDED RELEASE) | IPSEN BIOPHARMACEUTICALS CANADA INC | MARKETED | DIN 02283417 |
| SOMATULINE AUTOGEL | 60 MG | SOLUTION (EXTENDED RELEASE) | IPSEN BIOPHARMACEUTICALS CANADA INC | MARKETED | DIN 02283395 |
Who else supplies LANREOTIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LANREOTIDE appears in 96 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.